These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28705153)

  • 1. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
    Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
    Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
    Drain PK; Kubiak RW; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Sukrakanchana PO; Tanasri S; Punyati P; Sirirungsi W; Cressey R; Bacchetti P; Okochi H; Baeten JM; Gandhi M; Cressey TR
    Clin Infect Dis; 2020 May; 70(10):2143-2151. PubMed ID: 31314073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
    Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
    J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
    Else LJ; Dickinson L; Edick S; Zyhowski A; Ho K; Meyn L; Dilly-Penchala S; Thompson B; Shaw V; Khoo S; Brand RM
    J Antimicrob Chemother; 2024 Jul; 79(7):1597-1605. PubMed ID: 38758205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.
    Gandhi M; Bacchetti P; Spinelli MA; Okochi H; Baeten JM; Siriprakaisil O; Klinbuayaem V; Rodrigues WC; Wang G; Vincent M; Cressey TR; Drain PK
    J Acquir Immune Defic Syndr; 2019 May; 81(1):72-77. PubMed ID: 30664078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark Study.
    Wu L; Saina M; Brown C; Chege D; Donnell D; Glidden DV; Ngure K; Mugo NR; Akelo N; Schaafsma T; Anderson PL; Mugwanya KK
    Front Reprod Health; 2024; 6():1325257. PubMed ID: 38860025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L; Niu X; Brunelli MK; Mugwanya KK
    Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
    Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
    PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.
    Gandhi M; Bacchetti P; Rodrigues WC; Spinelli M; Koss CA; Drain PK; Baeten JM; Mugo NR; Ngure K; Benet LZ; Okochi H; Wang G; Vincent M
    EClinicalMedicine; 2018; 2-3():22-28. PubMed ID: 30906930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.